基于定量药理的华法林个体化给药

张进华, 彭文星, 董婧, 刘晓芹, 焦正

中国药学杂志 ›› 2018, Vol. 53 ›› Issue (19) : 1703-1708.

PDF(1750 KB)
PDF(1750 KB)
中国药学杂志 ›› 2018, Vol. 53 ›› Issue (19) : 1703-1708. DOI: 10.11669/cpj.2018.19.016
论著

基于定量药理的华法林个体化给药

  • 张进华1, 彭文星1,2, 董婧3,4, 刘晓芹3,5, 焦正3*
作者信息 +

Individualized Medication of Warfarin by Quantitative Pharmacology

  • ZHANG Jin-hua1, PENG Wen-xing1,2, DONG Jing3,4, LIU Xiao-qin3,5, JIAO Zheng3*
Author information +
文章历史 +

摘要

目的 介绍华法林个体化给药的两种常用计算方法——多元线性回归法(MLR)和最大后验贝叶斯法(MAPB),为临床指导华法林的个体化给药提供参考。方法 介绍MLR和MAPB在华法林精准给药中的原理,以及实现MLR和MAPB的计算工具,并通过5个华法林个体化给药的典型案例,重点介绍了MAPB计算工具的功能,包括制定华法林初始给药方案、调整给药方案以及其在特殊场景中的应用。结果与结论 MLR计算简单,但一般只可用于制定初始给药方案,无法进行剂量调整,临床应用受到了一定的限制。应用MAPB可制定个体化的华法林给药方案并可根据国际标准化比值(INR)进行剂量调整,预测误差小,还可用于判断患者用药依从性、指导停药时间等特殊情况,灵活性更好,可作为有效的临床辅助工具大力推广,应用前景广阔。

Abstract

OBJECTIVE To introduce two commonly used algorithms for warfarin individualized medication——multiple regression analysis(MRA)and maximum a posterior Bayesian (MAPB), and provide reference for individualized medication of warfarin in clinical practice. METHODS The principles of MRA and MAPB for warfarin individualized medication, as well as the decision support tools to realize MRA and MAPB, were introduced. The function of MAPB tool, including formulating an initial dosage regimen, adjusting the regimen and its application in special clinical situations, was described by five typical cases.RESULTS AND CONCLUSION MLR is simple to calculate, however, it can only be used to formulate the initial dosage regimen and dose adjustment cannot be carried out, which limits it clinical application in a certain extent. The application of MAPB can not only develop individualized medication of warfarin and adjust dose according to international normalized ratio(INR) with satisfactory prediction performance, but also be applied in special cases with better flexibility, such as judging medication adherence and instructing withdrawal. It could serve as an effective decision support tool to be promoted vigorously, which has a promising prospect.

关键词

华法林 / 多元线性回归法 / 最大后验贝叶斯法 / 个体化给药

Key words

warfarin / multiple regression analysis / maximum a posterior Bayesian / individualized medication

引用本文

导出引用
张进华, 彭文星, 董婧, 刘晓芹, 焦正. 基于定量药理的华法林个体化给药[J]. 中国药学杂志, 2018, 53(19): 1703-1708 https://doi.org/10.11669/cpj.2018.19.016
ZHANG Jin-hua, PENG Wen-xing, DONG Jing, LIU Xiao-qin, JIAO Zheng. Individualized Medication of Warfarin by Quantitative Pharmacology[J]. Chinese Pharmaceutical Journal, 2018, 53(19): 1703-1708 https://doi.org/10.11669/cpj.2018.19.016
中图分类号: R969.1   

参考文献

[1] HIRSH J,FUSTER V,ANSELL J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy . Circulation, 2003, 107(12):1692-1711.
[2] INTERNATIONAL WARFARIN PHARMACOGENETICS C,KLEIN T E,ALTMAN R B, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data . N Engl J Med, 2009, 360(8):753-764.
[3] JOHNSON J A,CAUDLE K E,GONG L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing:2017 Update . Clin Pharmacol Ther, 2017, 102(3):397-404.
[4] PELLAGATTI T,TERNELLI M,FRASCIO D, et al. Warfarin personalized dosage:re-compounding for a more suitable therapy and better compliance . Int J Pharm Compound, 2017, 21(3):247-250.
[5] MCMILLIN G A,VAZQUEZ S R,PENDLETON R C. Current challenges in personalizing warfarin therapy . Expert Rev Clin Pharmacol, 2011, 4(3):349-362.
[6] HUANG S W,CHEN H S,WANG X Q, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose:a prospective study in Chinese patients . Pharmacogenet Genomics, 2009, 19(3):226-234.
[7] EPSTEIN R S,MOYER T P,AUBERT R E, et al. Warfarin genotyping reduces hospitalization rates . J Am Coll Cardiol, 2010, 55(25):2804-2812.
[8] TAN D,YAN H,LUO Z Y, et al. Research progress of establishing the gene-guided dosing predictive model of warfarin . Chin J Clin Pharmacol Ther(中国临床药理学与治疗学), 2015, 20(12):1434-1440.
[9] LIN M Q,ZHANG J,YU L P, et al. Advances of individualized administration model of warfarin based on pharmacogenomics . Chin J Clin Pharmacol Ther(中国临床药理学与治疗学), 2014, 19(11):1299-1305.
[10] GAGE B F,EBY C,JOHNSON J A, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin . Clin Pharmacol Ther, 2008, 84(3):326-331.
[11] COSGUN E,LIMDI N A,DUARTE C W. High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans . Bioinformatics, 2011, 27(10):1384-1389.
[12] LIU K E,LO C L,HU Y H. Improvement of adequate use of warfarin for the elderly using decision tree-based approaches . Methods Inf Med, 2014, 53(1):47-53.
[13] HU J,ZHU J R,YU F. Dosing algorithms for warfarin individualized therapy . Chin J Clin Pharmacol The, 2014, 19(5):591-596.
[14] LING J,JIAO Z,ZHONG M K. Overviews and advances in studies of target concentration intervention . Chin Pharm J(中国药学杂志), 2013, 48(16):1337-1342.
[15] VAN DER MEER A F,MARCUS M A,TOUW D J, et al. Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation . Ther Drug Monit, 2011, 33(2):133-146.
[16] MOULD D R,D'HAENS G,UPTON R N. Clinical decision support tools:the evolution of a revolution . Clin Pharm Ther, 2016, 99(4):405.
[17] KUYPERS D R,LE M Y,CANTAROVICH M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation . Clin J Am Soc Nephrol Cjasn, 2010, 5(2):341.
[18] YE Z K,CHEN Y L,CHEN K, et al. Therapeutic drug monitoring of vancomycin:a guideline of the division of therapeutic drug monitoring, Chinese pharmacological society . J Antimicrob Chemother, 2016, 71(11):3020-3025.
[19] ROBERTS J A,ABDUL-AZIZ M H,LIPMAN J, et al. Individualised antibiotic dosing for patients who are critically ill:challenges and potential solutions . Lancet Infect Dis, 2014, 14(6):498-509.
[20] WRIGHT D F,DUFFULL S B. A Bayesian dose-individualization method for warfarin . Clin Pharmacokinet, 2013, 52(1):59-68.
[21] HAMBERG A K,DAHL M L,BARBAN M, et al. A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy . Clin Pharmacol Ther, 2007, 81(4):529-538.
[22] SASAKI T,TABUCHI H,HIGUCHI S, et al. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with bayesian forecasting . Pharmacogenomics, 2009, 10(8):1257-1266.
[23] WRIGHT D F,DUFFULL S B. Development of a bayesian forecasting method for warfarin dose individualization . Pharm Res, 2011, 28(5):1100-1111.
[24] LIN R F,LIN W W,WANG C L, et al. Population pharmacokinetic/pharmacodynamic modeling of warfarin by nonlinear mixed effects model . Acta Pharm Sin(药学学报), 2015(10):1280-1284.
[25] XUE L,HOLFORD N,DING X L, et al. Theory-based pharmacokinetics and pharmacodynamics of S-and R-warfarin and effects on international normalized ratio:influence of body size, composition and genotype in cardiac surgery patients . Br J Clin Pharmacol, 2017, 83(4):823-835.
[26] ZHANG J H, FU F, WU J M, et al. A case discussion of individualized administration of of warfarin by maximum aposteriori bayesian estimation method. China Pharm(中国药师),2018,21(3):435-443.
[27] AVERY P J,JORGENSEN A,HAMBERG A K, et al. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy . Clin Pharmacol Ther, 2011, 90(5):701-706.
[28] MAREK E,MOMPER J D,HINES R N, et al. Prediction of warfarin dose in pediatric patients:an evaluation of the predictive performance of several models . J Pediatr Pharmacol Ther, 2016, 21(3):224-232.
[29] HAMBERG A K,FRIBERG L E,HANSEUS K, et al. Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithms . Eur J Clin Pharmacol, 2013, 69(6):1275-1283.
[30] HAMBERG A K,WADELIUS M,LINDH J D, et al. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age . Clin Pharmacol Ther, 2010, 87(6):727-734.
[31] HAMBERG A K,HELLMAN J,DAHLBERG J, et al. A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children . BMC Med Inform Decis Mak, 2015,15(1):1-9.
[32] JIAO Z. The use of individualized administration softuare. . http://www.linyaoquan.com/kecheng/detail_1622893?f=org_coursecenter.20180511/20080716.

基金

留学回国人员科研启动项目资助(2015B001);福建省科技计划引导性项目资助(2018Y0037);上海市卫生计生系统重要薄弱学科建设计划项目资助(2016ZB0301-01)
PDF(1750 KB)

Accesses

Citation

Detail

段落导航
相关文章

/